Prophylactic treatment in cancer patients undergoing antineoplastic therapy during the COVID-19 pandemic.
Drug: Azithromycin 500 milligram (mg) oral Tablet
weekly oral use
Drug: Placebo
weekly oral use
Inclusion Criteria:
- Histologically confirmed cancer diagnosis
- Ongoing systemic antineoplastic treatment irrespective of application route
- Age ≥ 18 years
- Life expectancy of at least 3 months
- Adequate renal, cardiac and liver function
- Corrected QT time (QTc) ≤ 450 ms
- Eastern Cooperative Oncology Group (ECOG) performance status of < 3
- Capable of understanding the study and giving informed consent
- Negative COVID-19 test at study entry as measured by routine testing
Exclusion Criteria:
- Use of any investigational agent within 28 days prior to study start
- Patients with active opportunistic infections
- Pregnant or lactating women
- Women of childbearing potential and male subjects not willing to use adequate
contraception methods during the study period
- Hypersensitivity to azithromycin or other macrolides
- Concurrent medication with ergotamine, theophylline, digitalis
- Inability to swallow tablets
AKH Vienna, Department for Internal Medicine I, Oncology
Vienna, Austria